



INVESTIGATION INTO THE MOLECULAR SPECIFICITY OF THE IGFs: A CHIMERIC APPROACH

By

Adam Denley, BBiotech (Hons.)

**A Thesis submitted to the University of Adelaide, South Australia
in fulfilment of the requirements for the degree of
Doctor of Philosophy**



**School of Molecular and Biomedical Science
The University of Adelaide
Adelaide, South Australia.
December, 2004**

ABSTRACT

Insulin-like growth factors (IGF)-I and -II induce a variety of cellular outcomes including cell proliferation, differentiation, cell migration and protection from apoptosis. IGF-I and IGF-II share a high degree of structural similarity reflecting their high level of sequence similarity. Despite this both IGF-I and IGF-II exhibit different binding affinities to almost all proteins with which they both interact. To date few studies have investigated the structural basis whereby IGF-I and IGF-II bind with different affinities to the type-1 IGF receptor (IGF-1R), insulin receptor (IR) isoforms, type-2 IGF receptor (IGF-2R) and IGF binding proteins (IGFBPs). The major objective of this thesis is to investigate the molecular basis for the unique receptor and binding protein binding properties of IGF-I and IGF-II

To address the question of what parts of IGF-I and IGF-II confer their unique receptor and binding protein binding affinities, chimeras of IGF-I and IGF-II were engineered where their C and D domains were exchanged either singly or together. These are the first ever whole domain chimeras of IGF-I and IGF-II. Recently the alternatively spliced isoform of the insulin receptor lacking 12 amino acids encoded by exon 11 (IR-A) has been shown to be overexpressed in foetal and cancer tissues and bind IGF-II but not IGF-I with high affinity. Binding analysis of the engineered chimeras to the IR-A showed that the C and D domains of IGF-II allow high affinity binding whereas the same domains of IGF-I preclude high affinity binding to the IR-A. The C and D domains also regulate the differential interaction of IGF-I and IGF-II with the insulin receptor isoform containing the amino acids encoded by exon 11 (IR-B). The C domain of IGF-II, in the background of IGF-II or IGF-I, also allows potent induction of phosphorylation of various tyrosine residues in the intracellular β

subunits of the IR-A and IR-B, whereas the same domain of IGF-I in the background of IGF-II did not. In addition this same domain also is the molecular basis for the differential ability of IGF-II and IGF-I to phosphorylate IRS-1 and activate PKB/Akt. Furthermore, the differential ability of IGF-II and IGF-I to induce cell survival and promote cell migration via the IR-A is due to their C domains.

The IGF-IR binds IGF-I with a 3-5 fold higher affinity than IGF-II. Here in this thesis the differential affinity of IGF-I and IGF-II for the IGF-IR is shown to be in a large part due to their C and D domains.

The IGF-2R is a receptor that does not contain any intrinsic signaling activity and in the context of the IGF system appears to regulate the concentration of IGF-II. IGF-2R binds IGF-II with high affinity but binds IGF-I with very low affinity. Reported here is the novel identification of the IGF-II C domain as an important contributor for wildtype IGF-2R binding. IGFBPs act to both potentiate and inhibit the cellular actions of the IGFs. Almost all IGFBPs bind IGF-I and IGF-II with different affinities, particularly IGFBP-6 which has a 10-60 fold higher affinity for IGF-II compared to IGF-I. Binding analysis of IGF chimeras to IGFBP-1, -2, -3 revealed that the C and D domains of the IGFs do not regulate any IGFBP affinity difference, however the IGF-II C domain may play a small role in binding to IGFBP-6.

Recently a patient exhibiting mental retardation, short stature and gonadal dysfunction was shown to be homozygous for a mutation in his IGF-I gene resulting in a protein with a methionine instead of a valine at position 44. Here in this thesis the biochemical characterization of this mutant is reported. This mutation causes almost a 90-fold reduction in IGF-IR binding affinity, while completely abrogating binding to either IR isoform. Interestingly binding to IGFBP-2, -3 and -6 is unaffected. In addition, NMR analysis showed only small perturbations in the structure localized around the site of the mutation.

In conclusion this thesis has contributed to the understanding of ligand receptor interactions of the insulin/IGF system.

TABLE OF CONTENTS

ABSTRACT	I
STATEMENT OF ORIGINALITY	IV
ACKNOWLEDGEMENTS	V
TABLE OF CONTENTS	VII
LIST OF PUBLICATIONS	XIV
ABBREVIATIONS	XVII
CHAPTER 1: INTRODUCTION	1
1.1 INTRODUCTION.....	2
1.1.1 <i>Introduction to the IGF axis</i>	3
1.2 IGF EXPRESSION AND TRANSCRIPTIONAL REGULATION	6
1.2.1 <i>IGF Structure and Function</i>	8
1.3 INSULIN-LIKE GROWTH FACTOR I RECEPTOR (IGF-1R) – STRUCTURE AND FUNCTION.....	12
1.3.1 <i>IGF-1R signalling</i>	13
1.3.2 <i>Role of the IGF-1R in cancer</i>	16
1.3.3 <i>IGF residues involved in IGF-1R binding</i>	17
1.3.4 <i>Summary of IGF residues involved in IGF-1R binding</i>	22
1.3.5 <i>Mechanism of IGF binding to the IGF-1R</i>	23
1.4 INSULIN RECEPTOR.....	23
1.4.1 <i>Insulin receptor (IR) – structure and function</i>	24
1.4.3 <i>Insulin receptor isoforms</i>	28
1.4.4 <i>Insulin receptor isoform tissue distribution</i>	30
1.4.5 <i>The role of the insulin receptor isoforms in cancer</i>	31
1.4.6 <i>The role of insulin receptor isoforms in type 2 diabetes</i>	34
1.4.7 <i>Residues of IGF that are involved in IR binding</i>	37
1.4.8 <i>Summary of IGF residues involved in IR binding</i>	42
1.4.9 <i>Mechanism of insulin binding to the IR</i>	43
1.5 HYBRID IR/IGF-1R	46
1.6 THE INSULIN-LIKE GROWTH FACTOR TYPE 2 RECEPTOR (IGF-2R)	48

1.6.1 IGF residues involved in IGF-2R binding	50
1.6.2 Summary of IGF residues involved in IGF-2R binding	53
1.6.3 Mechanism of IGF-II binding to the IGF-2R.....	53
1.7 INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS (IGFBPs)-STRUCTURE AND FUNCTION	54
1.7.1 IGF residues involved in IGFBP binding	55
1.7.2 Summary of IGF residues involved in IGFBP binding.....	62
1.7.3 Mechanism of IGF-I and IGF-II binding to IGFBPs.....	62
1.8 COMPARISON OF THE RECEPTOR AND BINDING PROTEIN BINDING SITES ON THE IGFs.....	63
1.9 AIMS AND EXPERIMENTAL STRATEGY	64

**CHAPTER 2: CONSTRUCTION OF VECTORS FOR IGF CHIMERA
EXPRESSION** 67

2.1 INTRODUCTION	68
2.2 GENERAL MATERIALS	71
2.2.1 Bacterial media and buffers.....	71
2.2.2 Bacterial Strains	71
2.3 MATERIALS FOR MOLECULAR BIOLOGY	72
2.3.1 Molecular Biology Solutions.....	72
2.3.2 Kits For Molecular Biology.....	73
2.3.3 Expression Vector	73
2.3.4 ●ligonucleotides	75
2.4 METHODS	75
2.4.1 Agarose Gel Electrophoresis ●f DNA.....	75
2.4.2 Restriction Enzyme Digestion ●f DNA.....	76
2.4.3 Purification ●f DNA By Denaturing Polyacrylamide Gel Electrophoresis	76
2.4.4 Polymerase Chain Reaction (PCR)	77
2.4.5 Purification ●f PCR Products From Agarose Gels.....	77
2.4.6 TA Cloning ●f PCR Fragments	78
2.4.7 Dye Terminator DNA Sequencing	79
2.4.8 Removal ●f 5'-Phosphate From Vector	79
2.4.9 DNA Ligation.....	80
2.4.10 Preparation ●f Competent Cells	80
2.4.11 Bacterial Transformations	81

2.5 RESULTS AND DISCUSSION	81
2.5.1 Codon Optimisation Of Sequences For Expression.....	82
2.5.2 Strategy to Construct Coding Sequence for IGF chimeras	83
2.5.3 Summary	86

CHAPTER 3: EXPRESSION AND PURIFICATION OF HUMAN IGF-I, IGF-II AND NOVEL IGF CHIMERAS..... 87

3.1 INTRODUCTION	88
3.2 MATERIALS.....	91
3.2.1 Expression and Purification buffers	92
3.2.2 Protein Electrophoresis buffers	
3.2.3 BIAcore buffers	
3.3 METHODS	94
3.3.1 Analytical HPLC.....	94
3.3.2 Expression Of Proteins In <i>E. coli</i>	94
3.3.3 SDS Polyacrylamide Gel Electrophoresis	95
3.3.4 Lysis Of <i>E. coli</i> By French Press	95
3.3.5 Gel Filtration	96
3.3.6 Refolding Of Fusion Proteins	97
3.3.7 Ion Exchange Chromatography.....	97
3.3.8 Hydroxylamine Cleavage.....	98
3.3.9 α -Lytic Protease Cleavage	98
3.3.10 Preparative Reverse Phase HPLC.....	98
3.3.11 Freeze Drying	99
3.3.12 Quantitation Of Purified Protein.....	99
3.3.13 Mass Spectrometry And N-Terminal Sequencing	100
3.3.14 BIAcore Analyses	101
3.4 RESULTS	102
3.4.1 IGF-I.....	102
3.4.2 IGF-II.....	104
3.4.3 IGF-I DII.....	104
3.4.4 IGF-I CII.....	105
3.4.5 IGF-I CHDII	105
3.4.6 IGF-II DI.....	105
3.4.7 IGF-II CI.....	106

3.4.8 IGF-II CIDI.....	106
3.4.9 BIAcore Analyses	106
3.4 DISCUSSION	108
CHAPTER 4: BINDING AND ACTIVATION OF IR-A AND IR-B BY INSULIN, IGF-II, IGF-I AND IGF CHIMERAS	113
4.1 INTRODUCTION	114
4.2 MATERIALS.....	118
4.3 METHODS	118
4.3.1 Construction ●of Cells Expressing The Human IR-A And IR-B	118
4.3.2 Binding Analyses ●of Chimeras To Insulin Receptor Isoforms	119
4.3.3 Insulin Receptor Phosphorylation Assays	120
4.4 RESULTS	121
4.4.1 Binding analyses of insulin, IGF-II, IGF-I and IGF chimeras to the IR-A	121
4.4.2 Binding analyses of insulin, IGF-II, IGF-I and IGF chimeras to the IR-B	123
4.4.3 Phosphorylation of the IR-A and IR-B by stimulation with chimeric IGFs	125
4.5 DISCUSSION	127
CHAPTER 5: INSULIN, IGF-II, IGF-I AND IGF CHIMERA SIGNALING THROUGH THE IR-A AND IR-B	136
5.1 INTRODUCTION	137
5.2 MATERIALS.....	141
5.3 METHODS	141
5.3.1 Construction ●of Cells Expressing The IR Isoforms.....	141
5.3.2 IR-A And IR-B Phosphorylation And Activation ●of Intra-Cellular Signalling Molecules In Response To Insulin, IGF-I, IGF-II And IGF Chimeras	141
5.3.3 Western Blot Analysis	142
5.3.4 Migration Assays	143
5.3.5 Cell Survival Assays.....	144
5.4 RESULTS	144
5.4.1 A timecourse of phosphorylation of Y960 on the IR-A stimulated by insulin, IGF-II, IGF-I and IGF C domain chimeras.....	144
5.4.3 Induction of autophosphorylation of tyrosines in the activation loop of the IR-A and IR-B by insulin, IGF-II, IGF-I, and IGF chimeras.....	147

5.4.4 Activation of Y960 on IR-A and Y972 on IR-B by insulin, IGF-II, IGF-I, and IGF chimeras.....	150
5.4.5 Phosphorylation of IRS-1 by IR-A and IR-B activated by insulin, IGF-I, IGF-II, and IGF chimeras.....	152
5.4.6 Phosphorylation of IRS-2 by IR-A and IR-B activated by insulin, IGF-I, IGF-II, and IGF chimeras.....	154
5.4.7 Activation of Akt/PKB by insulin, IGF-II, IGF-I, and IGF chimeras in R ¹ IR-A and R ¹ IR-B cells	156
5.4.8 Activation of Erk1/2 by insulin, IGF-II, IGF-I, and IGF chimeras in R ¹ IR-A and R ¹ IR-B cells.....	158
5.4.9 R ¹ IR-A cell protection from sodium butyrate-induced apoptosis by Insulin, IGF-II, IGF-I, and IGF chimeras.....	160
5.4.10 Insulin, IGF-I, IGF-II, and IGF chimera stimulated chemotaxis of R ¹ IR-A cells.....	162
5.5 DISCUSSION.....	163

CHAPTER 6: BINDING AND ACTIVATION OF THE HUMAN IGF-1R BY INSULIN, IGF-II, IGF-I AND IGF CHIMERAS 170

6.1 INTRODUCTION	171
6.2 MATERIALS.....	173
6.3 METHODS	173
6.4 RESULTS	174
6.4.1 Binding of insulin, IGF-II, IGF-I and IGF chimeras to the IGF-1R.....	174
6.4.2 Phosphorylation of the IGF-1R by stimulation with chimeric IGFs	176
6.5 DISCUSSION	179

CHAPTER 7: BINDING OF IGF-I, IGF-II AND IGF CHIMERAS TO THE IGF-2R AND IGFBPs 185

7.1 INTRODUCTION	186
7.1.1 Type II IGF receptor (IGF-2R).....	186
7.1.2 Insulin-like growth factor binding proteins (IGFBPs)	188
7.2 MATERIALS.....	190
7.3 METHODS	190
7.3.1 Production Of IGF-2R Fragments.....	190
7.3.2 BIAcore Analyses Of IGF-2R Interactions	190

7.3.3 <i>BIAcore Analyses Of IGFBP Interactions</i>	191
7.4 RESULTS	193
7.4.1 <i>Kinetic analysis of IGF-I, IGF-II and IGF chimeras binding to IGF-2R fragments</i>	193
7.4.2 <i>Kinetic analysis of IGF-I, IGF-II and IGF chimeras binding to IGFBP-1, -2, -3 and -6</i>	196
7.5 DISCUSSION	201
CHAPTER 8: STRUCTURAL AND FUNCTIONAL ANALYSIS OF VAL44MET IGF-I	205
8.1 INTRODUCTION	206
8.2 MATERIALS	208
8.3 METHODS	209
8.3.1 <i>Construction Of Expression Plasmids Encoding Human IGF-I And Val44Met IGF-I</i>	209
8.3.2 <i>Recombinant IGF-I And Val44Met IGF-I Production</i>	209
8.3.3 <i>Binding Analysis Of Val44Met IGF-I To The IGF-1R And IR Isoforms</i> ...	210
8.3.4 <i>IR And IGF-1R Phosphorylation Assays</i>	210
8.3.5 <i>BIAcore Analyses Of IGFBP Binding</i>	210
8.4 RESULTS	212
8.4.1 <i>Purification of Val44Met IGF-I</i>	212
8.4.2 <i>IGF-1R binding and activation</i>	212
8.4.3 <i>IR binding and activation</i>	214
8.4.4 <i>Receptor signalling and biological activity in fibroblasts</i>	216
8.4.5 <i>IGFBP binding</i>	217
8.4.6 <i>Structural Analysis of Val44Met IGF-I by NMR</i>	218
8.5 DISCUSSION	222
CHAPTER 9: FINAL DISCUSSION	227
9.1 DISCUSSION	228
9.2 SUMMARY OF FINDINGS	228
9.3 EVOLUTION OF THE IGFS	231
9.4 DIVERGENCE OF THE IGF-I AND IGF-II C AND D DOMAINS	232
9.5 WHICH C AND D DOMAIN RESIDUES CONFER SPECIFICITY AND WHY?	233
9.6 FUTURE DIRECTIONS	235

9.7 DESIGNING INHIBITORS OF IGF ACTION RATHER THAN OF IGF-1R ACTION	237
9.8 CONCLUSION.....	238
REFERENCES.....	240